Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alterin vitro oxidizability
✍ Scribed by O’Neal, D.N.; O’Brien, R.C.; Timmins, K.L.; Grieve, G.D.; Lau, K.P.; Nicholson, G.C.; Kotowicz, M.A.; Best, J.D.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 115 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0742-3071
No coin nor oath required. For personal study only.
✦ Synopsis
The aim of this study was to determine the effect of the lipid modifying agent gemfibrozil on lipid and coagulation risk factors in patients with Type 2 diabetes mellitus (Type 2 DM). Twenty-six subjects with Type 2 DM and dyslipidaemia were treated for 24 weeks with either gemfibrozil 600 mg orally twice daily or placebo in a double-blind randomized trial. Lipid profiles, fibrinogen, Factor VII, and plasminogen activator inhibitor-1 (PAI-1) were measured by routine laboratory methods. Low density lipoprotein (LDL) size was determined by gradient gel electrophoresis and the resistance of LDL to copper-induced oxidation was assessed by measuring absorbance at 234 nm. Gemfibrozil significantly reduced total cholesterol (-0.9 (-0.48, -1.32) mmol l -1 ; p Ͻ0.05) and triglycerides (-2.7 (-1.55, -1.35) mmol l -1 ; p Ͻ0.001) vs placebo. The fall in triglyceride was reflected by a fall in VLDL cholesterol levels in the gemfibrozil treated group vs placebo (-1.31 mmol l -1 ; p Ͻ0.001). LDL-cholesterol level did not change but LDL particle size increased by 0.5 nm (0.01, 0.93); P Ͻ0.02. The increase in particle size was inversely correlated with the change of triglyceride level (r = -0.79, p Ͻ0.0001) but did not result in any reduction of susceptibility to copper-induced oxidation. There were no significant changes in the coagulation parameters studied. Because of its ability to correct the lipid abnormalities associated with Type 2 DM particularly hypertriglyceridaemia, gemfibrozil provides a useful therapeutic option in the management of diabetic dyslipidaemia but it does not alter in vitro oxidizability of LDL.